Media coverage about Proteon Therapeutics (NASDAQ:PRTO) has been trending somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.6328471391531 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Proteon Therapeutics (NASDAQ:PRTO) remained flat at $1.80 on Wednesday. 91,131 shares of the company traded hands. The stock has a 50-day moving average price of $2.04 and a 200-day moving average price of $1.54. The firm’s market cap is $31.71 million. Proteon Therapeutics has a 52 week low of $1.10 and a 52 week high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.11. On average, equities analysts forecast that Proteon Therapeutics will post ($1.52) earnings per share for the current fiscal year.
Several research analysts have commented on the stock. HC Wainwright set a $2.00 target price on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research cut shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Proteon Therapeutics presently has an average rating of “Hold” and an average price target of $6.25.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
What are top analysts saying about Proteon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteon Therapeutics Inc. and related companies.